Document is current
Any future updates will be listed below
-
Authors
Kimura, Shun-ichi https://orcid.org/0000-0001-9827-8526
Shimizu, Hiroaki
Miyazaki, Takuya
Sakurai, Masatoshi https://orcid.org/0000-0002-6687-4136
Tanoue, Susumu
Kayamori, Kensuke https://orcid.org/0000-0001-6140-3135
Ohwada, Chikako https://orcid.org/0000-0001-9648-940X
Yoshimura, Kazuki https://orcid.org/0000-0002-8013-1400
Nakasone, Hideki https://orcid.org/0000-0001-5812-9315
Ohashi, Takuma https://orcid.org/0000-0002-4354-2032
Shono, Katsuhiro https://orcid.org/0000-0002-5163-0163
Tachibana, Takayoshi https://orcid.org/0000-0002-7780-4459
Hatano, Kaoru
Okada, Keigo
Kimura, Yuta
Seo, Sachiko
Doki, Noriko
Tanaka, Masatsugu
Hatta, Yoshihiro
Takahashi, Satoshi https://orcid.org/0000-0002-1076-2338
Kanda, Yoshinobu https://orcid.org/0000-0002-4866-9307
,
- License Information
-
More Information
Article History
Received: 6 September 2022
Revised: 8 December 2022
Accepted: 12 December 2022
First Online: 26 December 2022
Competing interests
: S-IK has received personal fees from Asahi Kasei, Sumitomo Dainippon Pharma, Merck Sharp & Dohme, Astellas, Pfizer, Kyowa Kirin, Chugai Pharmaceutical Co., Ltd., Bristol-Myers Squibb, Ono Pharmaceutical Co., Ltd., Eisai Co., Ltd., Takeda Pharmaceutical Co., Ltd., SymBio Pharmaceuticals Ltd., Amgen Co., Ltd., Meiji Seika Pharma Co., Ltd., and Nippon Kayaku. MS received research support from Nippon Shinyaku and owns stock in Celaid Therapeutics. HN has received honoraria from Takeda Pharmaceutical, Otsuka Pharmaceutical, Bristol-Myers Squibb, Pfizer, Novartis, Janssen Pharmaceutical, Eisai, Chugai Pharmaceutical, Sanofi, and Nippon Shinyaku. TT reports service on speakers bureaus from Otsuka, Novartis, Pfizer, MSD, abbvie, and Amgen, outside the submitted work. YKanda received honoraria from Merck Sharp & Dohme, Pfizer, Astellas Pharma, Janssen, Chugai Pharma, Otsuka, Sumitomo Dainippon Pharma, Eisai, Novartis, Kyowa Hakko Kirin, Bristol-Myers Squibb, Takeda Pharmaceuticals, Alexion Pharmaceuticals, Shire, Daiichi Sankyo, Ono Pharmaceutical, Nippon Shinyaku, Mochida Pharmaceutical, Mundipharma, Sanofi and Meiji Seika Kaisha, and research funding from Astellas Pharma, Eisai, Otsuka, Kyowa Hakko Kirin, Sanofi, Shionogi, Taiho Pharmaceutical, Chugai Pharma, Nippon Shinyaku and Pfizer. The other authors have no competing interests to declare.
